shutterstock_1147238582_testing
Testing / Shutterstock.com
30 July 2020BiotechnologySarah Morgan

Roche stakes $2bn on UCB Alzheimer’s disease treatment

Swiss company  Roche has partnered with Belgium-based biopharmaceutical company  UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

More on this story

Americas
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

More on this story

Americas
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.